NeurAxis, Inc. commercializes neuromodulation therapies for chronic and debilitating conditions in children and adults. The company’s proprietary IB-Stim product uses Percutaneous Electrical Nerve Field Stimulation, or PENFS, and is FDA cleared for functional abdominal pain associated with irritable bowel syndrome, functional dyspepsia, and FD-related nausea symptoms in patients 8 years and older.
Recurring NeurAxis news includes FDA clearance updates, reimbursement and coding developments, medical policy coverage decisions, commercial access through payer and government channels, and adoption of PENFS in clinical practice. Company updates also cover quarterly financial results, business update calls, preferred stock dividends, equity and balance-sheet activity, and changes involving licensed neuromodulation assets.
NeurAxis (NRXS) announced new medical policy coverage from a national health insurer for approximately 26 million additional medical plan members.
The coverage spans multiple states and expands the national coverage footprint for PENFS, electrical stimulation of nerves in the ear, to over 147 million covered lives. IB-Stim is the company’s proprietary PENFS technology.
NeurAxis is hiring additional sales professionals following Craig Blanchard’s recent appointment as Chief Commercial Officer. The company anticipates further coverage gains from major insurers and believes broader coverage and an expanded commercial team position it for revenue growth and margin expansion.
NeurAxis (NRXS) appointed Craig Blanchard chief commercial officer to oversee its sales and marketing functions. The company expects to expand its commercial organization and anticipates a substantial increase in covered lives as it seeks broader adoption of IB-Stim. Blanchard previously held commercial leadership roles at NICO, Boston Scientific and Guidant.
NeurAxis (NRXS) received new medical policy coverage from a major national health insurer for its Percutaneous Electrical Nerve Field Stimulation (PENFS) therapy on September 16, 2026, adding access for approximately 18 million health plan members.
This expansion increases the total U.S. coverage footprint for PENFS to over 120 million covered lives. NeurAxis’ proprietary PENFS device, IB-Stim, is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) and functional dyspepsia (FD), including FD-related nausea, in patients 8 years and older. The company highlights that there are currently no FDA-approved drug therapies for pediatric abdominal pain related to functional dyspepsia. A Category I CPT code for PENFS became effective January 1, 2026, supporting reimbursement and commercialization efforts.
NeurAxis (NRXS) will present and meet with investors at the virtual Lytham Partners Fall 2026 Investor Conference on September 29-30, 2026.
The company’s webcast presentation is scheduled for 11:45 a.m. ET on Tuesday, September 29, 2026, and can be accessed via the conference site at https://lythampartners.com/fall2026/ or directly at https://app.webinar.net/lJ5aBmzWwkZ. A replay will be available after the event. Management will also participate in virtual one-on-one meetings with investors, which can be arranged by contacting Lytham Partners at 1x1@lythampartners.com or by registering at https://lythampartners.com/fall2026invreg/.
NeurAxis (NYSE American: NRXS) reported record second quarter 2026 results, with revenues rising 116% year over year to $1.93 million, driven by increased payer coverage following the January 1, 2026 Category I CPT code for Percutaneous Electrical Nerve Field Stimulation (PENFS).
Unit deliveries grew 60% year over year and gross margin improved to 85.9% from 83.6%, reflecting a shift from discounted assistance programs to fully reimbursed procedures. Cash stood at $8.3 million on June 30, 2026, with operating cash use reduced to $1.0 million versus $1.5 million a year earlier.
The company highlighted several milestones: VA Federal Supply Schedule contract award, first-ever FDA clearance for IB-Stim in functional dyspepsia abdominal pain (ages 8+), and pediatric guidelines recommending its PENFS technology for functional abdominal pain in IBS.
NeurAxis (NYSE American: NRXS) announced new medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) therapy, adding access for over 500,000 covered lives and expanding IB-Stim availability for beneficiaries in the Mid-Atlantic region.
According to NeurAxis, this incremental coverage supports its strategy to achieve comprehensive nationwide written policy coverage for IB-Stim. The company highlights implementation of a Category I CPT code and inclusion of its PENFS technology in leading clinical guidelines as reinforcing IB-Stim’s clinical and economic value among payers. IB-Stim is FDA-cleared for functional abdominal pain associated with IBS and functional dyspepsia, including FD-related nausea, in patients 8 years and older, and is positioned as the only FDA-cleared therapy specifically designed for pediatric abdominal pain-related DGBIs.
NeurAxis (NYSE American: NRXS) will release summarized financial results for its second quarter ended June 30, 2026, before market open on Tuesday, August 11, 2026. The company will host a conference call the same day at 9:00 a.m. ET to review the results, with live phone and webcast access plus a replay option.
NeurAxis (NYSE American: NRXS) reported record Q1 2026 revenue of $1.6 million, up 80% year over year, with unit deliveries up 35%. Gross margin rose to 86.4%, and operating loss declined 24%, supported by expanded insurance coverage from the new Category I CPT® code.
Cash was $7.1 million on March 31, 2026, plus $2.1 million raised afterward. NeurAxis highlighted new FDA clearances for IB-Stim, VA Federal Supply Schedule access, and pediatric guideline recommendations, broadening its addressable market.
NeurAxis (NYSE American: NRXS) will report summarized financial results for the first quarter 2026, for the period ended March 31, 2026, on Tuesday, May 12, 2026 before market open. The company also scheduled a conference call the same day at 9:00 AM ET to review results, with webcast and replay details provided.
Dial-in numbers, webcast link, and replay access code are available for investors and analysts to listen live or access the replay.
NeurAxis (NYSE: NRXS) announced four additional medical policies for Percutaneous Electrical Nerve Field Stimulation (PENFS), adding approximately 1.25 million covered lives and extending access in West Virginia, New Hampshire, South Carolina, Virginia, and Florida.
The company cited Category I CPT code recognition, inclusion in clinical guidelines, FDA clearance of IB-Stim for specified DGBI indications in patients age 8+, and disclosed an auditor’s explanatory paragraph noting substantial doubt about going concern for fiscal year 2025.